Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity

Area of Science:

• Immunology
• Cell Biology
• Biotechnology

Background:

• Immature dendritic cells (DCs) are crucial for inducing immune tolerance.
• Maintaining DC immaturity and interleukin-10 (IL-10) production is essential for tolerance induction.
• Dexamethasone (Dex) is investigated for its potential to create tolerogenic DCs.

Purpose of the Study:

• To develop dendritic cells (DCs) with sustained immaturity and tolerogenic properties using dexamethasone (Dex).
• To evaluate the stability of these Dex-modified DCs (Dex-DC) after Dex removal.
• To assess the IL-10 production and T-cell stimulatory capacity of Dex-DCs.

Main Methods:

• Human monocytes were differentiated into DCs in the presence of 10(-7) M Dex.
• Flow cytometry was used to analyze DC surface markers (CD1a, CD40, CD80, CD86, HLA-DR, CD83).
• Lipopolysaccharide (LPS) or CD40 ligand stimulation was used to assess DC maturation.
• IL-10 and IL-12 production was measured.
• Extracellular signal-regulated kinase (ERK) phosphorylation was assessed.
• T-cell proliferation assays were performed.

Main Results:

• Dex-treated DCs (Dex-DC) showed reduced expression of maturation markers (CD40, CD80, CD86, CD83) compared to control DCs (Ctrl-DC).
• Dex-DC maintained immaturity and high IL-10 production, with low IL-12, even 5 days after Dex removal.
• IL-10 production was linked to ERK phosphorylation, which remained high in Dex-DC post-removal.
• Dex-DC exhibited significantly lower T-cell proliferation activity.

Conclusions:

• Dexamethasone (Dex) can generate IL-10-producing dendritic cells (DCs) with durable immaturity.
• These Dex-modified DCs demonstrate reduced T-cell stimulatory capacity.
• Dex-treated DCs hold promise for inducing immune tolerance in therapeutic applications.